quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:24:25·43d
INSIDERFiling
Vaxcyte Inc. logo

SEC Form 4 filed by Vaxcyte Inc.

PCVX· Vaxcyte Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • PCVX
    Vaxcyte Inc.
    Health Care

Recent analyst ratings

  • Jan 7UpdateNeedham$110.00
  • Sep 12UpdateGoldman$38.00
  • Apr 22UpdateCantor Fitzgerald-
  • Dec 20UpdateGoldman$135.00
  • Dec 7UpdateMizuho$69.00
  • Apr 18UpdateTD Cowen-

Related

  • SEC10h
    SEC Form DEFA14A filed by Vaxcyte Inc.
  • SEC10h
    SEC Form DEF 14A filed by Vaxcyte Inc.
  • INSIDER15d
    SEC Form 4 filed by Cowan Elvia
  • PR16d
    Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
  • INSIDER20d
    SEC Form 4 filed by Wassil Jim
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.
  • PR29d
    Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
  • PR31d
    Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022